In line with its ACVR1-mediated inhibition of hepcidin expression, resulting in iron mobilization from cellular stores and enhanced erythropoiesis (Fig. 1), momelotinib has provided a constellation of important benefits with respect to anemia in MF patients. The gene discussed is ACVR1; the disease is anemia (phenotype).